AI assistant
BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2018
Jan 2, 2018
30583_dirs_2018-01-02_4e373c86-8f37-4aa3-899f-ec1e1c8fbc5e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2017-12-28
Reporting Person: BIENAIME JEAN JACQUES (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-09-26 | Common Stock | G | 430 | — | Disposed | 226494 | Direct |
| 2017-12-14 | Common Stock | G | 600 | — | Disposed | 225894 | Direct |
| 2017-12-28 | Common Stock | M | 10000 | $38.59 | Acquired | 235894 | Direct |
| 2017-12-28 | Common Stock | S | 10000 | $89.8912 | Disposed | 225894 | Direct |
| 2017-12-29 | Common Stock | M | 10000 | $38.59 | Acquired | 235894 | Direct |
| 2017-12-29 | Common Stock | S | 10000 | $89.6125 | Disposed | 225894 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-12-28 | Stock Option (Right to buy Common Stock) | $38.59 | M | 10000 | Disposed | 2018-05-21 | Common Stock (10000) | Direct |
| 2017-12-29 | Stock Option (Right to buy Common Stock) | $38.59 | M | 10000 | Disposed | 2018-05-21 | Common Stock (10000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 182801 | Indirect |
Footnotes
F1: On September 26, 2017, the reporting person gifted 430 shares to an educational institution.
F2: On December 14, 2017, the reporting person gifted 600 shares to an educational institution.
F3: Trade made pursuant to a 10b5-1 plan executed on November 14, 2017.
F4: The price in column 4 is the weighted average price. The price actually received ranged from $88.89 to $90.92. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
F5: Reflects the number of stock options outstanding after the transaction from this specific stock option grant.
F6: The price in column 4 is the weighted average price. The price actually received ranged from $88.97 to $90.45. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.